Patents by Inventor Kanako Tatsumi
Kanako Tatsumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158785Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: ApplicationFiled: January 12, 2024Publication date: May 16, 2024Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Patent number: 11912989Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: GrantFiled: February 23, 2021Date of Patent: February 27, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Publication number: 20240059774Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: September 19, 2023Publication date: February 22, 2024Inventors: Hitoshi KATADA, Kanako TATSUMI, Yutaka MATSUDA, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORI, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroki HAYASHI, Hiroaki SUSUMU
-
Publication number: 20240043515Abstract: In one non-limiting embodiment, polypeptides comprising a variant Fc region which contains amino acid alterations in a parent Fc region, and methods for producing such polypeptides, are provided.Type: ApplicationFiled: August 27, 2021Publication date: February 8, 2024Inventors: Hitoshi KATADA, Kanako TATSUMI
-
Publication number: 20240002510Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2022Publication date: January 4, 2024Inventors: Hitoshi KATADA, Kanako TATSUMI, Yutaka MATSUDA, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORI, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroki HAYASHI, Hiroaki SUSUMU, Shimon SAKAGUCHI
-
Publication number: 20230416371Abstract: In one non-limiting embodiment, polypeptides comprising a variant Fc region which contains amino acid alterations in a parent Fc region, and methods for producing such polypeptides, are provided.Type: ApplicationFiled: August 28, 2020Publication date: December 28, 2023Inventors: Hitoshi KATADA, Kanako TATSUMI
-
Publication number: 20230322898Abstract: The present invention provides a pharmaceutical composition comprising cells expressing a chimeric receptor, for use in combination with administration of an antigen-binding molecule, wherein the chimeric receptor comprises an extracellular domain, the extracellular domain comprises an extracellular domain of an immunoreceptor, an extracellular domain variant of an immunoreceptor, or a portion thereof, and the antigen-binding molecule is a multispecific antigen-binding molecule having a target antigen recognition site and an immunoreceptor recognition site which recognizes the immunoreceptor.Type: ApplicationFiled: July 30, 2021Publication date: October 12, 2023Applicants: Chugai Seiyaku Kabushiki Kaisha, Yamaguchi UniversityInventors: Tomoyuki Igawa, Mika Sakurai, Takashi Suzuki, Kanako Tatsumi, Shun Shimizu, Koji Tamada, Yukimi Sakoda
-
Publication number: 20230279099Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: April 25, 2023Publication date: September 7, 2023Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Patent number: 11673947Abstract: The present inventors discovered that problems of existing antibody pharmaceuticals can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: GrantFiled: August 13, 2019Date of Patent: June 13, 2023Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20230058982Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: December 27, 2019Publication date: February 23, 2023Inventors: Hitoshi KATADA, Kanako TATSUMI, Kanako ATSUMI, Shun SHIMIZU, Masaki KAMIMURA, Yasunori KOMORII, Yuji HORI, Tomoyuki IGAWA, Hiroki KAWAUCHI, Hiroaki SUSUMU
-
Publication number: 20230020377Abstract: The present disclosure provides anti-CTLA-4 antibodies and methods of producing and using the antibodies. The present disclosure also provides nucleic acids encoding the anti-CTLA-4 antibodies and host cells containing the nucleic acids. Furthermore, the present disclosure provides polypeptides containing a variant Fc region containing amino acid alterations in a parent Fc region and methods of producing and using the polypeptides.Type: ApplicationFiled: June 24, 2022Publication date: January 19, 2023Inventors: Hitoshi KATADA, Kanako Tatsumi, Yutaka Matsuda, Shun Shimizu, Masaki Kamimura, Yasunori Komori, Yuji Hori, Tomoyuki Igawa, Hiroki Kawauchi, Hiroki Hayashi, Hiroaki Susumu, Shimon Sakaguchi
-
Publication number: 20210324099Abstract: An objective of the present disclosure is to provide anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, and methods of using the same. Anti-CD137 antigen-binding molecules which have immunocyte-activating effect, cytotoxic activity, or anti-tumor activity, and meanwhile have reduced effect on non-tumor tissues such as normal tissues and produce less side effects, are provided by discovering and producing CD137 antigen-binding molecules whose binding activity to CD137 depends on various substances (for example, small molecule compounds) in target tissues. Methods of using the same, pharmaceutical formulations, and such are also provided. The present disclosure also provides an antigen-binding molecule whose binding activity to an antigen varies depending on a small molecule compound, a preparation method thereof, and uses thereof.Type: ApplicationFiled: August 9, 2019Publication date: October 21, 2021Inventors: Tomoyuki IGAWA, Mika SAKURAI, Shun SHIMIZU, Yuji HORI, Naoka HIRONIWA, Nasa SAVORY, Yoshinori NARITA, Takayuki KAMIKAWA, Taro MIYAZAKI, Shojiro KADONO, Masami HASEGAWA, Kanako TATSUMI, Akira HAYASAKA, Takeaki KAWAI, Futa MIMOTO, Hiroki KAWAUCHI, Masaki KAMIMURA
-
Publication number: 20210180049Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: ApplicationFiled: February 23, 2021Publication date: June 17, 2021Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Patent number: 10961530Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: GrantFiled: December 4, 2014Date of Patent: March 30, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Publication number: 20190359704Abstract: The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: August 13, 2019Publication date: November 28, 2019Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono
-
Publication number: 20160304862Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: ApplicationFiled: December 4, 2014Publication date: October 20, 2016Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki IGAWA, Shigero TAMBA, Shun SHIMIZU, Kanako TATSUMI, Shojiro KADONO, Hiroki KAWAUCHI, Kazuhiro OHARA, Masayuki MATSUSHITA, Takashi EMURA, Masaki KAMIMURA
-
Publication number: 20150166654Abstract: The present inventors discovered that the above-mentioned problems can be solved by producing antigen-binding molecules that contain an antigen-binding domain whose antigen-binding activity varies depending on the concentration of a target tissue-specific compound. Use of antigen-binding molecules of the present invention enables various diseases that originate from a target tissue to be treated in a manner specific to the target tissue.Type: ApplicationFiled: May 30, 2013Publication date: June 18, 2015Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Tomoyuki Igawa, Shigero Tamba, Kanako Tatsumi, Shun Shimizu, Shojiro Kadono